 |
|
|
|
 |
|
|
| Article 1 to 10 out of 16 concerning OctoPlus N.V.
|
-
OctoPlus proves efficacy of OP-145 in Phase II ear infection study
(29 Jul 2008)
OctoPlus N.V. announced that efficacy of OP-145, a novel therapy for the treatment of chronic middle ear infection (otitis media), was demonstrated in an interim analysis of the Phase II study. As a result, OctoPlus will close the study because its ...
-
OctoPlus presents positive Locteron Phase IIa study results at EASL conference
(25 Apr 2008)
OctoPlus N.V. presented extended results from its successful SELECT-1 Phase IIa clinical trial of Locteron® for the treatment of chronic hepatitis C (HCV) at the 43rd Annual Meeting of the European Association for the Study of Liver Diseases (EASL). ...
-
OctoPlus publishes Phase I Locteron results
(14 Mar 2008)
OctoPlus N.V. announced the publication of results from its Phase I study with Locteron®, its controlled-release formulation of alfa interferon for the treatment of chronic hepatitis C, in the current issue of the Journal of Interferon & Cytokine ...
-
OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
(12 Feb 2008)
OctoPlus N.V. announced the commencement of patient dosing in a Phase IIa study in the United States with Locteron®, its controlled-release formulation of alfa interferon for treatment of chronic hepatitis C (HCV). This study will expand upon the ...
-
OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
(16 Oct 2007)
OctoPlus N.V. announced the successful completion of the Phase IIa clinical study with its lead product Locteron(TM), a controlled release interferon alfa product for the treatment of chronic hepatitis C (HCV).According to the company, results from ...
-
OctoPlus in-licenses diabetes product candidate
(28 Sep 2007)
OctoPlus N.V. announced that it has acquired exclusive worldwide rights to develop and commercialise a family of compounds, including a GLP-1 agonist product candidate for the treatment of type 2 diabetes from Canadian biopharmaceutical company ...
-
OctoPlus announces promising results for Locteron Phase IIa clinical study
(30 Jul 2007)
OctoPlus N.V. announced positive initial results of the ongoing SELECT-1 Phase IIa study with its lead product Locteron(TM) , a controlled release interferon alfa for the treatment of chronic hepatitis C (HCV). In the 12-week Phase IIa study, the ...
-
OctoPlus gains full rights to PolyActive drug delivery technology from IsoTis
(26 Apr 2007)
OctoPlus N.V. announced that it reached agreement with IsoTis, Inc. to obtain additional rights to its PolyActive(TM) drug delivery technology, the technology used in OctoPlus' lead product Locteron(TM). Locteron is a controlled release formulation ...
-
OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C
(01 Feb 2007)
OctoPlus N.V. announced the commencement of a Phase IIa study with LocteronTM, its controlled release formulation of alfa interferon for treatment of chronic hepatitis C. The Phase IIa study is designed to evaluate Locteron in combination with the ...
-
OctoPlus announces official opening of Boston office
(10 Jan 2007)
OctoPlus N.V. announced the official opening of its business development office in Boston. According to the company, a large and growing part of OctoPlus' clients is located in North America. With the office in Boston, OctoPlus aims to better ...
Additional information
OctoPlus N.V.
Leiden, Netherlands
Company
|
|
|
|
|
|
Top
